Clinical Trials Logo

Malignant Neoplasm clinical trials

View clinical trials related to Malignant Neoplasm.

Filter by:

NCT ID: NCT06207864 Recruiting - Malignant Neoplasm Clinical Trials

Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing

PE-CGS
Start date: March 22, 2022
Phase: N/A
Study type: Interventional

This clinical trial studies engagement strategies for recruiting American Indians (AI) of Southwestern Tribal Nations for cancer genome sequencing. American Indians in the Southwest have higher rates of some types of cancer, such as cancers that arise in the liver, kidney, breast, and colon. American Indians with cancer may also live for less time than people from other population groups who have been treated for the same cancer. Damage to the cells of the body, acquired as people live, grow older, and are exposed to the environment, causes genetic changes in cells that can lead to cancer. This study may help researchers learn how these genetic changes in cells cause cancer and understand how and why cancer is arising in American Indians in the Southwest. This may help better prevent and treat cancer in the future.

NCT ID: NCT06206642 Completed - Malignant Neoplasm Clinical Trials

Comparing 18F-FAPI-04 and 18F-FDG PET/CT in Cancer Detection

Start date: April 1, 2022
Phase: N/A
Study type: Interventional

Evaluating fluoro-18-fibroblast activation protein inhibitor-04 positron emission computed tomography's diagnostic efficacy for primary malignancies versus 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose.

NCT ID: NCT06202534 Recruiting - Malignant Neoplasm Clinical Trials

An Observational Clinical Study Plan on the Effects of Radiotherapy on the Immune System of Patients With Malignant Tumors.

Start date: August 8, 2023
Phase:
Study type: Observational [Patient Registry]

To explore the impact of radiotherapy on peripheral blood myeloid-derived suppressor cells (MDSCs), T cells and extramedullary erythroid precursor cells in patients with malignant tumors, and to evaluate the correlation between changes in the proportion of these cells before and after radiotherapy and the efficacy of radiotherapy in patients.

NCT ID: NCT06186427 Recruiting - Cancer Clinical Trials

A Novel 68Ga Labeled FAP Ligand PET/CT in Patients With Various Malignant Tumors

68Ga-GPFAPI
Start date: January 13, 2024
Phase: N/A
Study type: Interventional

The investigators designed and synthesized a novel fibroblast activation protein (FAP) ligand (DOTA-GPFAPI-04) by assembling three functional moieties: a quinoline-based FAP inhibitor for specifically targeting FAP, a FAP substrate Gly-Pro as a linker for increasing the FAP protein interaction, and a 2,2',2",2‴-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetic acid (DOTA) chelator for radiolabeling with different radionuclides. Molecular docking studies investigated the FAP targeting ability of DOTA-GPFAPI-04. DOTA-GPFAPI-04 was then radiolabeled with 68Ga to give 68Ga-DOTA-GPFAPI-04 for positron emission tomography (PET) imaging. The investigators found that the 68Ga-DOTA-GPFAPI-04 has high stability, targeted specificity, and longer retention time. The tumor-to-muscle (T/M) ratio for 68Ga-DOTA-GPFAPI-04 reached 9.15.

NCT ID: NCT06090266 Recruiting - Cancer Clinical Trials

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

Start date: October 24, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR502 administered as a monotherapy and in combination with cemiplimab in subjects with advanced solid tumors.

NCT ID: NCT06051760 Not yet recruiting - Malignant Neoplasm Clinical Trials

NV-001 in the Treatment of Advanced Solid Tumors

Start date: December 1, 2023
Phase: Phase 1
Study type: Interventional

This study is a single-center, open, dose-escalation Phase I clinical study. It is designed to evaluate the safety, tolerability, preliminary efficacy and immunogenicity of treating NV-001, a king of hybrid-membrane-based tumor vaccine in patients with advanced solid tumors.

NCT ID: NCT06012695 Recruiting - Malignant Neoplasm Clinical Trials

NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma

Start date: August 11, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

NBM-BMX is an orally available new chemical entity to inhibit histone deacetylases 8 (HDAC8) activity specifically, being developed as a potential anti-cancer therapeutic by NatureWise. This study aims to evaluate the safety, pharmacokinetics, and preliminary efficacy of NBM-BMX as monotherapy in subjects with advanced solid tumors or combination with the standard of care treatment in subjects with newly diagnosed glioblastoma.

NCT ID: NCT05918445 Recruiting - Malignant Neoplasm Clinical Trials

PM8002 in the Treatment of Patients With Advanced Solid Tumors

Start date: March 9, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of PM8002, a PD-L1/VEGF bispecific antibody, as a single agent in adult subjects with advanced solid tumors.

NCT ID: NCT05886764 Recruiting - Cancer Clinical Trials

Novel Outreach Methods to Increase Enrollment to Early Phase Clinical Trials

Start date: October 23, 2023
Phase: N/A
Study type: Interventional

This trial will study different outreach methods to assess impact on enrollment of underrepresented minorities (specifically African Americans) to early phase cancer clinical treatment trials. Both patients and providers (those seeing enrolled patients) will be enrolled and receive the study interventions or no intervention (control arm).

NCT ID: NCT05835570 Recruiting - Malignant Neoplasm Clinical Trials

Integrin αvβ6-targeted PET in Malignant Tumors

Start date: January 1, 2023
Phase:
Study type: Observational

Malignant tumors are a significant health threat with high incidence and mortality rates, and molecular imaging is crucial for early diagnosis, staging, prognosis evaluation, and therapeutic efficacy assessment. 18F-FDG PET imaging is widely used, but has limitations. Integrin αvβ6 is a promising target for tumor-targeted imaging, as it is only expressed in cancerous or reconstructed epithelial cells. A new PET probe, 68Ga-Trivehexin, targeting integrin αvβ6 has been developed with better affinity and selectivity than previous probes. Clinical data supports its safety and metabolic stability, and future research will explore its diagnostic and staging value in different types of tumors and compare it to 18F-FDG, providing a new and precise evaluation method for malignant tumors.